{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:55:43Z","timestamp":1794268543842,"version":"4.9.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.transci.2023.103706","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T06:14:57Z","timestamp":1679379297000},"page":"103706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic modalities in thrombotic thrombocytopenic purpura management among Jehovah\u2019s Witness patients: A review of reported cases"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9974-5277","authenticated-orcid":false,"given":"Minh-Ha","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2023.103706_bib1","unstructured":"Online content accessed 11\/27\/22: \u3008https:\/\/www.jw.org\/en\/jehovahs-witnesses\/faq\/how-many-jw\/\u3009."},{"issue":"12","key":"10.1016\/j.transci.2023.103706_bib2","first-page":"826","article-title":"Transfusion replacement strategies in Jehovah\u2019s Witnesses and others who decline blood products","volume":"18","author":"DeLoughery","year":"2020","journal-title":"Clin Adv Hematol Oncol"},{"issue":"21","key":"10.1016\/j.transci.2023.103706_bib3","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.transci.2023.103706_bib4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005792-196603000-00003","article-title":"Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature","volume":"45","author":"Amorosi","year":"1966","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.transci.2023.103706_bib5","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.7326\/0003-4819-51-6-1409","article-title":"Unusual remission in a case of thrombotic thrombocytopenic purpura syndrome following fresh blood exchange transfusions","volume":"51","author":"Rubenstein","year":"1959","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.transci.2023.103706_bib6","first-page":"219","article-title":"Exchange transfusions in the treatment of thrombotic thrombocytopenic purpura","volume":"13","author":"Bukowski","year":"1976","journal-title":"Semin Hematol"},{"key":"10.1016\/j.transci.2023.103706_bib7","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1056\/NEJM197712222972507","article-title":"Treatment of thrombotic thrombocytopenic purpura with plasma","volume":"297","author":"Byrnes","year":"1977","journal-title":"NEJM"},{"issue":"3","key":"10.1016\/j.transci.2023.103706_bib8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood.V50.3.413.413","article-title":"Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura","volume":"50","author":"Bukowski","year":"1977","journal-title":"Blood"},{"key":"10.1016\/j.transci.2023.103706_bib9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"Rock","year":"1991","journal-title":"NEJM"},{"key":"10.1016\/j.transci.2023.103706_bib10","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1365-2141.1996.d01-1800.x","article-title":"Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura","volume":"94","author":"Rock","year":"1996","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.transci.2023.103706_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jca.1003","article-title":"Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenia (TTP)","volume":"16","author":"Zeigler","year":"2001","journal-title":"J Clin Aph"},{"key":"10.1016\/j.transci.2023.103706_bib12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2141.2005.05418.x","article-title":"Members of the Canadian apheresis group and members of the Canadian association of apheresis nurses. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet","volume":"129","author":"Rock","year":"2005","journal-title":"Br J Haemtol"},{"key":"10.1016\/j.transci.2023.103706_bib13","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1423-0410.2007.00940.x","article-title":"Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura","volume":"93","author":"Scully","year":"2007","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2023.103706_bib14","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1537-2995.2007.01074.x","article-title":"Comparison and stability of ADAMTS13 activity in therapeutic plasma products","volume":"47","author":"Scott","year":"2007","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2023.103706_bib15","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1423-0410.2006.00884.x","article-title":"Normal levels of ADAMTS13 and factor H are present in pharmaceutically licensed plasma for transfusion (Octaplas) and in the universally applicable plasma (Uniplas) in development","volume":"92","author":"Heger","year":"2007","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2023.103706_bib16","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ajh.23527","article-title":"ADAMTS13 content in plasma-derived FVIII\/von Willebrand factor concentrates","volume":"88","author":"Peyvandi","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.transci.2023.103706_bib17","first-page":"721","article-title":"The in vitro reduction of viscosity of human tracheobronchial secretions by acetylcysteine","volume":"90","author":"Sheffner","year":"1964","journal-title":"Am Rev Respir Dis"},{"issue":"2","key":"10.1016\/j.transci.2023.103706_bib18","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1172\/JCI41062","article-title":"N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice","volume":"121","author":"Chen","year":"2011","journal-title":"J Clin Investig"},{"issue":"5","key":"10.1016\/j.transci.2023.103706_bib19","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/trf.12440","article-title":"Treatment of refractory thrombotic thrombocytopenia with N-acetylcysteine: a case report","volume":"54","author":"Li","year":"2014","journal-title":"Transfusion"},{"issue":"4","key":"10.1016\/j.transci.2023.103706_bib20","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s11239-015-1259-6","article-title":"The role of N-acetylcysteine in the treatment of thrombotic thrombocytopenic purpura","volume":"41","author":"Rottenstreich","year":"2016","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"10.1016\/j.transci.2023.103706_bib21","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/0036933018775240","article-title":"Relapsed\/refractory thrombotic thrombocytopenic purpura treated with N-acetylcysteine: a case report","volume":"63","author":"Demircioglu","year":"2018","journal-title":"Scott Med J"},{"issue":"10","key":"10.1016\/j.transci.2023.103706_bib22","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Investig"},{"issue":"5","key":"10.1016\/j.transci.2023.103706_bib23","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/jca.22002","article-title":"\u201cPlasma exchange in a bottle\u201d: An overview of efgartigimod for apheresis practitioners","volume":"37","author":"Tran","year":"2022","journal-title":"J Clin Aph"},{"key":"10.1016\/j.transci.2023.103706_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.118074","article-title":"IgG regulation through FcRN blocking: a novel mechanism for the treatment of myasthenia gravis","volume":"430","author":"Wolfe","year":"2021","journal-title":"J Neurol Sci"},{"issue":"5","key":"10.1016\/j.transci.2023.103706_bib25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1182\/blood.2019000954","article-title":"How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns","volume":"134","author":"Mazepa","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.transci.2023.103706_bib26","unstructured":"Caplacizumab Package Insert: accessed 6\/26\/22 \u2013 \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761112s000lbl.pdf\u3009."},{"issue":"6","key":"10.1016\/j.transci.2023.103706_bib27","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"NEJM"},{"issue":"4","key":"10.1016\/j.transci.2023.103706_bib28","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"NEJM"},{"key":"10.1016\/j.transci.2023.103706_bib29","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/1098-1101(2000)15:4<266::AID-JCA9>3.0.CO;2-9","article-title":"Management of a Jehovah\u2019s Witness with thrombotic thrombocytopaenic purpura\/haemolytic uraemic syndrome","volume":"15","author":"Drummond","year":"2000","journal-title":"J Clin Aph"},{"key":"10.1016\/j.transci.2023.103706_bib30","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/jca.20150","article-title":"Successful management of a Jehovah\u2019s Witness with thrombotic thrombocytopenic purpura unwilling to be treated with therapeutic plasma exchange","volume":"22","author":"Dabak","year":"2007","journal-title":"J Clin Aph"},{"issue":"2","key":"10.1016\/j.transci.2023.103706_bib31","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4103\/0973-6247.83255","article-title":"Thrombotic thrombocytopenic purpura treated with vincristine in a Jehovah\u2019s Witness","volume":"5","author":"Walia","year":"2011","journal-title":"Asian J Transfus Sci"},{"key":"10.1016\/j.transci.2023.103706_bib32","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/jca.21325","article-title":"Successful management of thrombotic thrombocytopenic purpura in a Jehovah\u2019s Witness without plasma exchange","volume":"30","author":"Chai","year":"2015","journal-title":"J Clin Aph"},{"issue":"24","key":"10.1016\/j.transci.2023.103706_bib33","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/bloodadvances.2017012351","article-title":"Management of thrombotic thrombocytopenic purpura without plasma exchange: the Jehovah\u2019s witness experience","volume":"1","author":"George","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.transci.2023.103706_bib34","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/tme.12407","article-title":"Pegylated bovine carboxyhaemoglobin utilization in a thrombotic thrombocytenic purpura patient","volume":"27","author":"Sam","year":"2017","journal-title":"Transfus Med"},{"key":"10.1016\/j.transci.2023.103706_bib35","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/jca.21710","article-title":"Survival of a Jehovah\u2019s Witness with thrombotic thrombocytopenic purpura without using plasma: a case report and review of the literature","volume":"34","author":"Baseri","year":"2019","journal-title":"J Clin Apher"},{"issue":"1","key":"10.1016\/j.transci.2023.103706_bib36","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/2374373519829902","article-title":"Successful management of thrombotic thrombocytopenic purpura in a Jehovah\u2019s Witness: An individualized approach with joint decision-making","volume":"7","author":"Lim","year":"2020","journal-title":"J Patient Exp"},{"key":"10.1016\/j.transci.2023.103706_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.5902","article-title":"Immune-mediated thromboic thrombocytopenic purpura in a Jehovah\u2019s Witness \u2013 Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab","volume":"10","author":"Cardesa-Salzmann","year":"2022","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.transci.2023.103706_bib38","doi-asserted-by":"crossref","unstructured":"Spencer C. , Abuhelwa Z. , Beran A. , Alsughayer A. , Sheikh T. , Oostra D. , , et al. Caplacizumab without plasma exchange for thrombotic thrombocytopenic purpura in a Jehovah\u2019s Witness. American Journal of Therapeutics, 2022 May 26, Online ahead of print.","DOI":"10.1097\/MJT.0000000000001522"},{"key":"10.1016\/j.transci.2023.103706_bib39","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ajh.20887","article-title":"Thrombotic thrombocytopenic purpura induced by trimethoprim-sulfamethoxazole in a Jehovah\u2019s Witness","volume":"82","author":"Martin","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.transci.2023.103706_bib40","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/trf.13285","article-title":"To treat or not to treat: a rare case of pseudo-thrombotic thrombocytopenic purpura in a Jehovah\u2019s Witness","volume":"56","author":"Malla","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2023.103706_bib41","first-page":"473","article-title":"Treatment of a Jehovah\u2019s Witness with recurrent thrombotic thrombocytopenic purpura with rituximab","author":"Kirti","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.transci.2023.103706_bib42","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMc1905426","article-title":"Caplacizumab therapy without plasma exchange for acquired thrombotic thrombocytopenic purpura","volume":"381","author":"Chander","year":"2019","journal-title":"NEJM"},{"issue":"4","key":"10.1016\/j.transci.2023.103706_bib43","first-page":"1","article-title":"Acquired thrombotic purpura successfully treated with caplacizumab without plasma transfusion in a Jehovah\u2019s Witness patient","volume":"10","author":"Desai","year":"2021","journal-title":"Int J Clin Stud Med Case Rep"},{"key":"10.1016\/j.transci.2023.103706_bib44","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/jca.20091","article-title":"Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the transfusion medicine\/hemostasis clinical trials network with systematic review of rituximab therapy for immune-mediated disorders","volume":"21","author":"George","year":"2006","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2023.103706_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1076029618825309","article-title":"Comparison of the long-term remission of rituximab and conventional treatment for acquired thrombotic thrombocytopenic purpura: A systematic review and meta-analysis","volume":"25","author":"Owattanapanich","year":"2019","journal-title":"Clin Appl Thromb\/Hemost"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050223000800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050223000800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:54:41Z","timestamp":1761468881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050223000800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1473050223000800"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2023.103706","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic modalities in thrombotic thrombocytopenic purpura management among Jehovah\u2019s Witness patients: A review of reported cases","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2023.103706","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103706"}}